About 38% of rads surveyed said they had defended against at least one lawsuit, with such specialists at a higher risk than others in internal medicine.
Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.
U.S. healthcare is in the throes of an affordability crisis. The good news is that healthcare leaders have all the evidence, tools and expertise needed to keep the predicament from becoming a plight. Can they marshal the will to wield those weapons toward that end?
Former ACC president Kim Allan Williams Sr., MD, shared his experience bringing helpful heart screenings to low-income neighborhoods. "You've got to be willing to go out and find where the patients are," he said.
Carmat is working to overcome financial struggles that forced it to suspend new device implants through the end of August. Even with its future in limbo, the company remains focused on moving forward.
Hospitals are awarded Honor Roll points if they rank in one or more of the 15 specialties that U.S. News evaluates, and in one or more of the 22 procedures or conditions for patient outcomes.
About 38% of rads surveyed said they had defended against at least one lawsuit, with such specialists at a higher risk than others in internal medicine.
Legal and compliance teams have to serve as sentinels sizing up potential legal exposure points without turning into needlers who only slow down clinical innovation.
